Please assess the completion status of the following clinical trial:

Trial Title: Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with B-precursor ALL relapsed after at least induction and consolidation or having refractory disease~* More than 5% blasts in bone marrow~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Life expectancy of ≥ 12 weeks~Exclusion Criteria:~* History or presence of clinically relevant central nervous system (CNS) pathology~* Infiltration of cerebrospinal fluid (CSF) by ALL~* Autologous/allogeneic hematopoietic stem cell transplantation (HSCT) within six weeks/three months prior to start of blinatumomab treatment~* Active Graft-versus-Host Disease (GvHD)~* Patients with Philadelphia chromosome (Ph)+ ALL eligible for treatment with dasatinib or imatinib~* Cancer chemotherapy within two weeks prior to start of blinatumomab treatment~* Immunotherapy (e.g. rituximab) within four weeks prior to start of blinatumomab treatment~* Infection with human immunodeficiency virus (HIV) or hepatitis B (HBsAg positive) or hepatitis C virus (anti-HCV positive)~* Pregnant or nursing women~* Previous treatment with blinatumomab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blinatumomab 15 μg (Type: EXPERIMENTAL): Participants received blinatumomab 15 μg/m²/day as a continuous intravenous infusion at a constant flow rate over 4 weeks followed by a 2-week treatment-free interval for up to 5 consecutive cycles.
- Blinatumomab 5/15 μg (Type: EXPERIMENTAL): Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, followed by 15 μg/m²/day starting from Week 2 of treatment.
- Blinatumomab 5/15/30 μg (Type: EXPERIMENTAL): Participants received blinatumomab by continuous intravenous infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 5 μg/m²/day for the first seven days of treatment, a dose of 15 μg/m²/day in the subsequent 7 days, followed by 30 μg/m²/day starting from Week 3 of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).